Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Blau

Showing results (81-90 of 129) with videos related to

Pageof 13
Sort By:
American Journal of Hematology|May 14, 2024
Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantationNico Gagelmann, Claudia Schuh, Sarah Flossdorf, et al.
Blood|September 17, 2013
CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMTMartin Schmidt-Hieber, Myriam Labopin, Dietrich Beelen, et al.
Blood Advances|July 21, 2023
EASIX-1year and late mortality after allogeneic stem cell transplantationLambros Kordelas, Tobias Terzer, Ted Gooley, et al.
Haematologica|September 21, 2010
Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agentsMartin Schmidt-Hieber, Julie Schwender, Werner J Heinz, et al.
British Journal of Pharmacology|March 23, 2013
MDMA 'ecstasy' increases cerebral cortical perfusion determined by bolus-tracking arterial spin labelling (btASL) MRIJ Rouine, O L Gobbo, M Campbell, et al.
Haematologica|November 28, 2015
Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myelomaNiels Weinhold, Desiree Kirn, Anja Seckinger, et al.
Leukemia|March 23, 2007
Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yieldI Breitkreutz, H M Lokhorst, M S Raab, et al.
The Lancet. Haematology|March 15, 2020
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trialMarc S Raab, Monika Engelhardt, Antje Blank, et al.
Hemasphere|October 23, 2024
Long-term outcome of 2-year survivors after allogeneic hematopoietic cell transplantation for acute leukemiaMarion Larue, Myriam Labopin, Thomas Schroeder, et al.
Haematologica|May 13, 2017
Longitudinal fluorescence <i>in situ</i> hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantationMaximilian Merz, Anna Jauch, Thomas Hielscher, et al.
Pageof 13

Showing results (81-90 of 129) with videos related to

Sort By:
Pageof 13
American Journal of Hematology|May 14, 2024
Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantationNico Gagelmann, Claudia Schuh, Sarah Flossdorf, et al.
Blood|September 17, 2013
CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMTMartin Schmidt-Hieber, Myriam Labopin, Dietrich Beelen, et al.
Blood Advances|July 21, 2023
EASIX-1year and late mortality after allogeneic stem cell transplantationLambros Kordelas, Tobias Terzer, Ted Gooley, et al.
Haematologica|September 21, 2010
Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agentsMartin Schmidt-Hieber, Julie Schwender, Werner J Heinz, et al.
British Journal of Pharmacology|March 23, 2013
MDMA 'ecstasy' increases cerebral cortical perfusion determined by bolus-tracking arterial spin labelling (btASL) MRIJ Rouine, O L Gobbo, M Campbell, et al.
Haematologica|November 28, 2015
Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myelomaNiels Weinhold, Desiree Kirn, Anja Seckinger, et al.
Leukemia|March 23, 2007
Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yieldI Breitkreutz, H M Lokhorst, M S Raab, et al.
The Lancet. Haematology|March 15, 2020
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trialMarc S Raab, Monika Engelhardt, Antje Blank, et al.
Hemasphere|October 23, 2024
Long-term outcome of 2-year survivors after allogeneic hematopoietic cell transplantation for acute leukemiaMarion Larue, Myriam Labopin, Thomas Schroeder, et al.
Haematologica|May 13, 2017
Longitudinal fluorescence <i>in situ</i> hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantationMaximilian Merz, Anna Jauch, Thomas Hielscher, et al.
Pageof 13